Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after ...
Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.
Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
DexCom (DXCM) shares rallied 5.6% in the last trading session to close at $80.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Connacht Rugby and the IRFU have announced that Dexcom Stadium will host the Guinness Women's Six Nations fixture between ...
A Raymond James analyst cut his price target on the specialty medical device maker. It was the second such price target cut so far this month. Raymond James prognosticator Jayson Bedford was the ...
IEEE Spectrum on MSN
Why the most accurate glucose monitors are failing some users
In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings. The recall affects approximately 3 million sensors and was caused by an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback